Emerging studies suggest Retatrutide , a dual agonist targeting both incretin and another hormone, could provide a promising development for obesity management . Early patient trials have shown considerable reductions in body fat , conceivably exceeding existing obesity medications . Nevertheless , further evaluation is needed to fully determine it